Skip to content

Measuring malaria transmission after drug treatment

The impact of anti-malarial treatment upon the development and persistence of Plasmodium falciparum gametocytes in vitro and in vivo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11805747
Enrollment
600
Registered
2005-07-22
Start date
2000-01-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria Infections and Infestations Malaria

Interventions

Combination antimalarial therapy versus established monotherapy. Single-blind open-label randomised controlled trial run over three consecutive transmission seasons in Farafenni, The Gambia.

Sponsors

London School of Hygiene and Tropical Medicine (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Children one to ten years of age (either sex) attending Farafenni Health Centre, The Gambia, from September to December in each of 2000, 2001 and 2002 2. Children with a temperature more than 37.5°C, or a history of fever 3. Blood-film positive for P. falciparum at a density greater than 500 parasites per ml 4. Signed informed consent was obtained

Exclusion criteria

Exclusion criteria: 1. An inability to take drugs orally 2. Treatment with antimalarial chemotherapy within the past two weeks 3. Carriage of circulating gametocytes at presentation 4. Any evidence of chronic disease or acute infection other than malaria 5. Domicile outside the study area (approximately 10 km radius) 6. Any signs or symptoms of severe malaria: 6.1. Severe anaemia (peripheral blood Packed Cell Volume [PCV] less than 20%) 6.2. Hyper-parasitaemia (more than 250,000 per ml peripheral blood) 6.3. Respiratory distress (respiratory rate more than 40 with two of the following: nasal flaring, intercostal indrawing, subcostal recession or grunting) 6.4. Repeated generalised convulsions (three or more per 24 hours or two witnessed seizures in 24 hours) 6.5. Haemoglobinuria (dark red/black urine) 6.6. Jaundice 6.7. Prostration 6.8. Circulatory collapse

Design outcomes

Primary

MeasureTime frame
Major endpoints were: 1. Post-treatment gametocyte carriage over 28 days 2. Infectiousness to mosquitoes of children carrying gametocytes seven days after treatment

Secondary

MeasureTime frame
Minor endpoints were: 1. Clinical and parasitological drug efficacy over 28 days of follow-up

Countries

Gambia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026